A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy (ARTEMIS - IGAN)

Protocol No
NEPH-ELMEANAWY-OMEROS2
Phase
III
Summary

This project is being done to test the safety and efficacy of OMS721 in individuals with IgA Nephropathy.

Description
Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Categories
Kidney Disease, Other
ClinicalTrials.gov
go to website